Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$84.84
+0.3%
$87.26
$51.79
$101.40
$11.51B11.81 million shs1.81 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$65.48
+5.7%
$58.23
$47.31
$87.32
$2.81B0.53882,817 shs1.04 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$328.46
+0.2%
$329.87
$221.26
$362.41
$12.90B0.74435,224 shs508,515 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.45%+10.88%-10.62%-6.34%+43.14%
Haemonetics Corporation stock logo
HAE
Haemonetics
+5.97%+16.22%+7.13%+6.92%-2.10%
Penumbra, Inc. stock logo
PEN
Penumbra
+0.20%+1.93%-1.21%-3.22%+21.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$84.84
+0.3%
$87.26
$51.79
$101.40
$11.51B11.81 million shs1.81 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$65.48
+5.7%
$58.23
$47.31
$87.32
$2.81B0.53882,817 shs1.04 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$328.46
+0.2%
$329.87
$221.26
$362.41
$12.90B0.74435,224 shs508,515 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.45%+10.88%-10.62%-6.34%+43.14%
Haemonetics Corporation stock logo
HAE
Haemonetics
+5.97%+16.22%+7.13%+6.92%-2.10%
Penumbra, Inc. stock logo
PEN
Penumbra
+0.20%+1.93%-1.21%-3.22%+21.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.81
Moderate Buy$106.3625.37% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.73
Moderate Buy$77.1117.76% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.18
Hold$361.3310.01% Upside

Current Analyst Ratings Breakdown

Latest PEN, HAE, and GMED Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
UpgradeNeutralBuy$72.00 ➝ $80.00
5/21/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
DowngradeHold (C-)Sell (D+)
5/12/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
Reiterated RatingOutperform
5/12/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
Lower Price TargetOutperform$94.00 ➝ $89.00
5/8/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
Set Price Target$67.00
5/8/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Lower Price TargetOverweight$104.00 ➝ $103.00
5/8/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Boost Price TargetOutperform$115.00 ➝ $120.00
5/8/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Boost Price TargetBuy$114.00 ➝ $117.00
5/8/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
Lower Price TargetNeutral$74.00 ➝ $62.00
5/7/2026
Penumbra, Inc. stock logo
PEN
Penumbra
Reiterated RatingOutperform$335.00
5/7/2026
Penumbra, Inc. stock logo
PEN
Penumbra
Lower Price TargetNeutral$374.00 ➝ $350.00
(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$3.10B3.71$6.30 per share13.47$34.86 per share2.43
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.33B2.23$8.01 per share8.17$17.52 per share3.74
Penumbra, Inc. stock logo
PEN
Penumbra
$1.40B9.20$4.31 per share76.27$37.47 per share8.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$4.3019.7316.801.7418.92%13.46%11.65%8/6/2026 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$97.31M$2.0232.4211.391.257.29%27.30%9.59%8/6/2026 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$177.69M$4.3475.6851.082.0111.76%10.87%8.45%8/4/2026 (Estimated)

Latest PEN, HAE, and GMED Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.92$1.12+$0.20$0.90$740.35 million$759.85 million
5/7/2026Q4 2026
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.28$1.29+$0.01-$0.44$336.83 million$346.35 million
5/6/2026Q1 2026
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06$0.82-$0.24$0.82$370.47 million$374.76 million
2/25/2026Q4 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$1.12-$0.37-$1.49-$0.52$367.18 million$385.39 million
2/24/2026Q4 2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.06$1.28+$0.22$1.03$803.29 million$826.42 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.56
2.95
Haemonetics Corporation stock logo
HAE
Haemonetics
1.53
2.95
1.87
Penumbra, Inc. stock logo
PEN
Penumbra
0.01
6.02
3.95

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
Penumbra, Inc. stock logo
PEN
Penumbra
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000135.75 million110.80 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02345.45 million45.62 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,70039.33 million38.19 millionOptionable

Recent News About These Companies

Penumbra: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Globus Medical stock logo

Globus Medical NYSE:GMED

$84.84 +0.23 (+0.27%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$84.90 +0.07 (+0.08%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics stock logo

Haemonetics NYSE:HAE

$65.48 +3.54 (+5.72%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$65.47 -0.01 (-0.02%)
As of 05/22/2026 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Penumbra stock logo

Penumbra NYSE:PEN

$328.46 +0.57 (+0.17%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$328.68 +0.23 (+0.07%)
As of 05/22/2026 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.